RÉPUBLIQUE DU CA	MEROUN			REPUI	BLQUE	E DU CAMEROU
Paix-Travail-Pa	trie		1	Pe	ace-W	ork-Fatherland
MINISTRY OF PUBLIC	C HEALTH		<b>S</b>	MIN	_	E DE LA SANTE BLIQUE
SECRETARIAT GE	NERAL	All.	N. P.	SEC	RETA	RIAT GENERAL
CELLULE DES INFOR SANITAIRES		MINS	ANTE	HEA		INFORMATION UNIT
NATIO	ONAL HEAL	TH IN	ORMATI	ON SY	YSTEI	М
MONTHLY PROGRESS		REGIONA HOSPIT		AL, GE	NERAI	L AND REFERRA
		- MPR	1 -			
			Month:			7
Year:	I. IDENTIFICATION OF THE HEALTH FACILITY					
237.1	ATION OF TH	E HEAL	TH FACILI	ТҮ		_
I. IDENTIFICA	ATION OF TH	E HEAL	TH FACILITY Subdiv			
I. IDENTIFICA						
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:	Division:	He	Subdivealth Area:	vision:		
I. IDENTIFICA  Region: Health District: Name of Health Facility: Status: Public	Division: Public Related	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:	Division:  Public Related Priv	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region: Health District:  Name of Health Facility:  Status: Public	Division:  Public Related Priv	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region: Health District:  Name of Health Facility:  Status: Public	Division:  Public Related Prive Facility:	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region: Health District: Name of Health Facility: Status: Public	Division:  Public Related Prive Facility:	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:  Status: Public	Division:  Public Related Prive Facility:	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:  Status: Public Lay private non-profit making Telephone number of the Health  Email:  Location (Town/Village/neighbour  Data entry date into DHIS2:  Name of data manager:	Public Related Prive Pacility:  rhood):	He	Subdivealth Area:	vision:	Den	ominational private
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:  Status: Public Lay private non-profit making Telephone number of the Health  Email:  Location (Town/Village/neighbour  Data entry date into DHIS2:  Name of data manager:  Telephone number of data manager	Public Related Prive Pacility:  rhood):	He	Subdivealth Area:	vision:	Den -	nominational private
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:  Status: Public Lay private non-profit making Telephone number of the Health  Email:  Location (Town/Village/neighbour  Data entry date into DHIS2:  Name of data manager:	Public Related Prive Facility:  rhood):	He	Subdiversity of the second sec	vision:	-	ominational private
I. IDENTIFICA  Region: Health District: Name of Health Facility: Status: Public	Public Related Prive Facility:  rhood):	He	Subdiversity of the second sec	vision:	-	
I. IDENTIFICA  Region: Health District: Name of Health Facility: Status: Public	Public Related Prive Facility:  rhood):	He	Subdiversity of the second sec	vision:	-	
I. IDENTIFICA  Region:  Health District:  Name of Health Facility:  Status: Public	Public Related Prive Facility:  rhood):	He	Subdiversity of the second sec	vision:	-	

# II. REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH)

# II.I MATERNAL HEALTH

	II.I.I ANTE NATAL CONSULTATIONS	10-14 yrs	15-19 rsYrs	> 19 rsyrsrs
I. Nu	mber of pregnant women below 15 years received during the month			
2. Nui	mber of pregnant women received for ANCI(Ist contact) during the month			
3. Nu	mber of pregnant women who attended their first ANC before 16 weeks			
4. Nu	mber of pregnant women received for ANC 4 and above during the month			
5. Nu	mber of pregnant women who received the first IPT dose			
6. Nu	mber of pregnant women who received the third IPT dose (complete IPT)			
	umber of pregnant women who received at least two doses of Tetanus vaccine uring the current pregnancy consulted during the month			
8. Nu	mber of women who received the I st dose of Tetanus vaccine during the month			
9. Nu	mber of women who received the 2 <sup>nd</sup> dose of Tetanus vaccine during the month			
I0. Nu	mber of women who received the 3 <sup>rd</sup> dose of Tetanus vaccine during the month			
II. Nu	mber of women who received the 4 <sup>th</sup> dose of Tetanus vaccine during the month			
12. Nu	mber of women who received the 5 <sup>th</sup> dose of Tetanus vaccine during the month			
13. Num mon	ber of women who received the I <sup>st</sup> dose of Tetanus Diphtheria vaccine during the th			
14. Num mon	ber of women who received the $2^{nd}$ dose of Tetanus Diphtheria vaccine during the th			
	al number of women received for ANC during the month and whose blood ssure was measured			
I6. Tot	al number of women received for ANC who did the syphilis test			
17. Nui	mber of diagnosed syphilis cases in pregnant women in ANC during the month			
18. Nui	mber of treated syphilis cases in pregnant women in ANC during the month			
19. Num	ber of pregnant women screened for Hepatitis B during the month			
20. Num	ber of pregnant women who tested positive to Hepatitis B during the month			

II.1.2 DELIVERIES, EMERGENCY, OBSTETRIC AND NEONATAL CARE	10-14 yrs	15-19 yrs	> 19 yrs
21. Total number of deliveries in the facility during the month			
22. Total number of deliveries recorded in the community during the month			
23. Number of women who benefited AMTSL during the month			
24. Number of deliveries with obstetrical complications:			
Number of cases of haemorrhage			
Number of cases of prolonged labour/dystocia			

Number of pre-eclampsia/eclampsia cases		
Number of cases of uterine ruptures		
Number of cases of puerperal infection		
25. Number of Caesarean sections performed		
26. Number of obstetrical complication cases managed or referred during the month		
27. Number of complicated abortion cases recorded in the health facility during the month		
28. Number of maternal deaths recorded in the health facility during the month		
29. Number of maternal deaths recorded in the community during the month		
30. Number of maternal deaths audited during the month		
27. Number of abortion-related deaths recorded during the month		
28. Number of women who initiated a family planning method in <b>immediate</b> post-partum during the month		

II.1.3 POST NATAL CONSULTATION	10-14 yrs	15-19 yrs	> 19 yrs
29. Number of women who initiated a family planning method during the post-partum period during the month			
30. Number of women who delivered and spent less than 48 hours in the health facility during the month			
31. Number of couples (women and newborns) who received at least one postnatal consultation within 48 hr following delivery			
32. Number of couples (mother and newborn) who received a postnatal consultation between the 6 <sup>th</sup> and the 10 <sup>th</sup> day following delivery			
33. Number of women who received Vitamin A during post-partum during the month			

II.1.4 BIRTHS	М	F
34. Number of live births recorded in the health facility during the month		
32. Total number of births recorded in the community during the month		
35. Number of birth declarations forwarded at the civil status centre during the month		
36. Number of premature live births recorded during the month		
37. Number of premature or low weight babies (less than 2500 g) administered Kangaroo care		
38. Number of new cases of sick infants received during the month (fever, jaundice, refusal to breastfeed, lethargy)		
39. Number of cases of birth asphyxia		
40. Number of cases of birth asphyxia resuscitation (with a mask and a balloon)		

41.	Number of recorded live births below2500 g	
42.	Number of stillbirths recorded in the health facility	
43.	Number of neonatal deaths that occurred during the first 24 hours	
44.	Number of neonatal deaths (0 to 28 days) recorded in the HF during the month	

II.1.5 FAMILY PLANNING		
45. Number of new users (additional clients)		
Number of users who chose one of the following contraceptive methods during the month	New	Old
Progesterone-only pill		
Oestrogen-Progesterone pill		
Morning-after pill		
Intramuscular Injections (Depo provera,)		
Subcutaneous Injections (Sayana Press)		
Implants		
IUD		
VSC: Voluntary Surgical Contraception (tubal ligation, vasectomy,)		
Male condoms		
Female condoms		
Natural method		_

11.2	SCREENING AND MANAGEMENT OF GENESIC CANCERS AND OBSTETRIC FISTULAS	
46.	Number of women aged between 30 to 49 years screened for cervical cancer	
47.	Number of breast cancer cases suspected	
48.	Number of breast cancer cases confirmed	
49.	Number of breast cancer cases managed	
50.	Number of breast cancer cases referred	
51.	Number of cervical cancer cases suspected	
52.	Number of cervical cancer cases confirmed	
53.	Number of cervical cancer cases managed	
54.	Number of cervical cancer cases referred	
55.	Number of obstetrical fistula cases screened	
56.	Number of obstetrical fistula cases managed	
57.	Number of obstetrical fistula cases screened and referred	
58.	Number of prostate cancer cases screened	
59.	Number of prostate cancer cases managed	
60.	Number of prostate cancer cases referred	

11.3	PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV	
61.	Number of pregnant women who did their first HIV test during the current pregnancy during the month	
62.	Number of pregnant women who collected their HIV test results during the month	
63.	Number of pregnant women who did their first HIV test and tested positive during the month	
64.	Number of pregnant women known to be HIV-positive during their first ANC visit	
65.	Number of pregnant women who tested negative during their first ANC visit, who were retested for HIV during the second, third, or fourth ANC during the month	
66.	Number of pregnant women who tested negative during their first ANC visit, who were retested for HIV and were diagnosed HIV-positive during the second, third, or fourth ANC during the month	
67.	Number of male partners of pregnant women received during the month who were screened for HIV	
68.	Number of male partners of pregnant women received during the month who tested HIV positive	
69.	Number of HIV-positive pregnant women who received Co-trimoxazole prophylaxis during the month	
70.	Number of HIV-positive pregnant women who initiated ARV triple therapy on site during the month	
71.	Number of HIV-positive pregnant women already on triple therapy during their first ANC visit during the month	
72.	Number of HIV-positive pregnant women in whom the search for clinical signs of TB was carried out during the month	
73.	Number of pregnant women who did their first HIV test during the current pregnancy in the labour room during the month	
74.	Number of pregnant women who did their first HIV test during their pregnancy in the labour room and diagnosed HIV-positive during the month	
75.	Number of pregnant women tested negative during ANC who were retested for HIV in the labour room during the month	
76.	Number of pregnant women who tested negative during ANC who were retested and diagnosed HIV-positive in the labour room during the month	
77.	Number of pregnant women who tested HIV-positive in the labour room and who initiated ART during the month	
78.	Number of women who gave birth in the health facility during the month	
79.	Number of HIV-positive women who gave birth in the HF during the month	
80.	Number of children born to HIV-positive mothers in the HF during the month	
81.	Number of children born to HIV-positive mothers who initiated Nevirapine therapy in post partum within 72 hours during the month	
82.	Number of HIV-positive women who gave birth out of the health facility and who came with their babies within 72 hours after delivery during the month	
83.	Number of women who initiated a family planning method during post-partum during the month	
84.	Number of HIV-positive women who initiated a family planning method in post-partum during the month	

11.3	PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV	
85.	Number of children born to HIV-positive mothers received for follow-up consultation between 6 and 10 days after delivery during the month	
86.	Number of children born to HIV-positive mothers received for follow-up consultation between 6 and 8 weeks during the month	
87.	Number of children born to HIV-positive mothers who initiated Cotrimoxazole from 6 weeks post partum during the month	
88.	Number of children born to HIV-positive mothers screened by PCR between 6 and 8 weeks during the	
89.	Number of children born to HIV-positive mothers screened by PCR between 6 and 8 weeks during the month	
90.	Number of children born to HIV-positive mothers screened by PCR between 8 weeks and 9 months during the month	
91.	Number of children born to HIV-positive mothers diagnosed HIV by PCR between 8 weeks and 9 months during the month	
92.	Number of children still on exclusive breastfeeding at 6 months of life during the month	
93.	Number of children born to HIV-positive mothers seen at the 9-month visit during the month	
94.	Number of children born to HIV-positive mothers seen at the $9^t$ -month visit who are up-to-date with their vaccinations	
95.	Number of children born to HIV-positive mothers diagnosed positive by serology between 9 to 18 months and screened by PCR during the month	
96.	Number of children born to HIV-positive mothers diagnosed positive by serology between 9 and 18 months and confirmed positive by PCR during the month	
97.	Number of children born to HIV-positive mothers and confirmed HIV infected by PCR and on ART during the month	

# III. CHILD HEALTH

### **III. CHILD AND ADOLESCENT HEALTH**

III.I CHILD IMMUNIZATION (EPI) AND ACTIVITIES/COMMUNICATION FOR IMMUNIZATION	0-11 months Number of sessions		12-59 months Persons sensitized
	Planned	Achieved	
98. Immunization in fixed strategy			
99. Immunization in advanced/mobile strategy			
100. Announcement by a town crier or sensitization with a megaphone			
101. Educational talk in the health facility			
102. Educational talk in the community/ associations			
103. Communication in churches			
104. Communication with traditional healers			
105. Search for the lost to follow up (number to be looked for and number found			

		0-I	I months			
III.2 IMMUNIZATION OF CHILDREN (EPI)	Fix	ed	Advance	ed/mobile	12-59 months	Refugees
	M	F	М	F		
106. Number of children who received BCG vaccine						
107. Number of children who received HepBO vaccine						
108. Number of children who received OPV0 vaccine						
109. Number of children who received OPV I vaccine						
IIO. Number of children who received OPV 2 vaccine						
III. Number of children who received OPV 3 vaccine						
II2. Number of children who received PVI vaccine						
II3. Number of children who received DTP+ HepBI+HibI (Penta I)						
114. Number of children who received DTP+ HepB3+Hib2 (Penta 2)						
II5. Number of children who received DTP+ HepB3+Hib3 (Penta 3)						
116. Number of children who received the first dose of the pneumonia vaccine (PCV-13-1)						
117. Number of children who received the second dose of the pneumonia vaccine (PCV-13-2)						
118. Number of children who received the third dose of the pneumonia vaccine (PCV-13-3)						
II9. Number of children who received Rota I						
120. Number of children who received Rota 2						
121. Number of children who received the first dose of measles/rubella vaccine						
I22. Number of children who received the second dose of measles/rubella vaccine						
123. Number of children who received the vaccine against yellow fever						
124. Number of children who received MenA vaccin						
125. Number of children who received Vitamin A						
126. Number of children who received one dose mebendazole during the month						

III.3 IMMUNIZATION OF ADOLESCENTS (EPI)	Fix	Advanced/mobi le	Refugees
127. Number of girls from 9 to 13 years old who received the first dose of HPV vaccine			
128. Number of girls from 9 to 13 years old who received the second dose HPV vaccine			
129. Number of girls from 9 to 13 years old who received the third dose of HPV vaccine			

III.4 STORAGE OF VACCINES AND WASTE MANAGEMENT	
130. Minimum temperature recorded	
131. Maximum temperature recorded	
I32. Number of low temperature alarms (number of temperature > +2°C)	
133. Number of high temperature alarms (number of temperature > +8°C)	
134. Number of safety boxes used	
135. Number of safety boxes destroyed	

# III.5 SURVEILLANCE OF AEFI (ADVERSE EFFECTS FOLLOWING IMMUNIZATION)

AEFI Type	No.	Antigen	Lot No.	Expiration Date
136. Fever > 48 hours				
137. Hives				
138. Adenopathies				
139. Abscess				
140. Anaphylactic shock				
141. Others (list them)				

III.6 INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESSES	
142. Number of diarrhoea cases recorded in children between 0 to 59 months	
143. Number of children between 0 to 59 months who received ORS + ZINC therapy (oral rehydration salts and Zinc) against diarrhoea	
144. Number of children between 0 to 59 months with pneumonia	
145. Number of children between 0 to 59 months with pneumonia who received an antibiotic treatment	

# IV. DISEASE CONTROL

### IV.I COMMUNICABLE DISEASES CONTROL

IV.I.I COMPREHENSIVE MANAGEMENT OF PLWHIV	< I	year	old	1 -	- 4 ye old	ars	5	-9 ye: old	ars	10	·14 ye	ears	15 -	·19 ye old	ears	20-	24 ye old	ars	25-	49 ye old	ars	>5	0 yea	ars	Т	ОТА	\L
	м	F	т	м	F	т	м	F	т	м	F	т	М	F	т	М	F	т	М	F	т	М	F	т	м	F	т
I46. Number of old PLWHIV on ART expected during the month																											
I47. Number of old PLWHIV on ART who received their treatment during the month																											
I48. Total number of new PLWHIV on ART who received their treatment during the month																											
I49. Total number of PLWHIV on ART who received their treatment during the month																											
I50. Total number of PLWHIV on first line ART who received their treatment during the month																											
151. Total number of PLWHIV on second line ART who received their treatment during the month																											
I52. Number of PLWHIV who switched from first to second line ART during the month																											
I53. Number of PLWHIV on Cotrimoxazole during the month																											
154. Number of PLHIV in whom TB clinical signs were investigated and documented during the month																											
155. Number of PLWHIV who initiated the treatment 12 months before the current month																											
156. Number of PLWHIV who did a CD4 count test (medical follow-up at 12 months) during the month																											

IV.I.I COMPREHENSIVE MANAGEMENT OF PLWHIV	< I	year	old	1 -	- 4 ye old	ars	5 -	9 ye: old	ars	10 -	14 ye old	ears	15 -	-19 ye old	ears	20-	24 ye old	ars	25-	49 ye old	ears	>5	0 yea	ars	Т	ОТА	\L
	м	F	т	м	F	т	м	F	т	м	F	т	М	F	т	М	F	т	М	F	т	М	F	т	М	F	т
157. Number of PLWHIV who did the viral load test 12 months before the initiation of the treatment during the month																											
I58. Number of PLWHIV on ART with a viral load suppression I2 months after the initiation of the treatment during the month																											
159. Number of PLWHIV still on treatment 12 months after the initiation during the month.																											
160. Number of reported PLWHIV who died during the month																											
161. Number of PLWHIV who did not collect their treatment during the month																											
162. Number of PLWHIV absent during the previous month who were found and their treatment reinitiated																											
163. Occasional aids (PLWHIV not followed up by ATC/MU but who came to collect their treatment during the month)																											
164. Number of blood exposure accidents (BEA) cases who received an ART																											
165. Number of old PLWHIV on ART who came to collect their treatment during the month																											
166. Number of old PLWHIV on ART who received their treatment during the month																											

### IV.I.I VOLUNTARY TESTING OF HIV/AIDS

		Number of persons counselled	Number of persons tested during the month	Number of persons who collected their	Number of persons tested HIV positive during the	Number of persons tested HIV positive and referred to the	Number of unspecified results during the month
		during the month	ule monui	results during the month	month	MU during the month	tile month
< 0	M						
≤ 9 years	F						
	Total						
10-14	M						
years	F						
	Total						
15-19	M						
years	F						
	Total						
20-24	M						
years	F						
	Total						
25-29	M						
years	F						
	Total						
30-34	M						
years	F						
	Total						
35-39	M						
years	F						
	Total						
40-44	M						
years	F						
	Total						
45-49	M						
years	F						
	Total						
≥ 50	M						
years	F						
	Total						
	M						
Total	F						
	Total						

IV.I.I MALARIA CONTROL	< 5years old	≥ 5 years old ( excluding PW)	Pregnant women (PW)
167. Number of Long Lasting Insecticide treated nets (LLINs) distributed			
168. Number of suspected uncomplicated malaria cases (clinical uncomplicated malaria)			
169. Number of cases suspected for severe malaria			
170. Number of Rapid Diagnostic Tests (RDT) done by the health staff			
171. Number of positive Rapid Diagnostic Tests (RDT)			
172. Number of thick smear tests done by the health personnel			
173. Number of positive thick smear tests			
174. Number of fever cases suspected to be uncomplicated malaria for which a confirmation test was not done (RDT or thick smear)			
175. Number of fever cases suspected to be severe malaria for which a confirmation test was not done (RDT or thick smear ))			
176. Number of uncomplicated malaria cases with positive RDT			
177. Number of uncomplicated malaria cases with a positive thick smear			
178. Number of severe malaria cases with a positive RDT			
179. Number of severe malaria cases with a positive thick smear			
180. Number of hospitalizations for confirmed severe malaria (with RDT or microscopy)	r		
181. Number of confirmed uncomplicated malaria cases treated by the health staff with ASAQ combination			
182. Number of confirmed uncomplicated malaria cases treated by the health staff with ACTs other than ASAQ			
183. Number of confirmed severe malaria cases treated with injectable artesunate			
184. Number of confirmed severe malaria cases treated with injectable arthemeter			
185. Number of confirmed severe malaria cases treated with injectable quinine			
186. Number of fever cases suspected to be uncomplicated malaria with negative RDT who received antimalarial treatment			
187. Number of uncomplicated malaria cases who received antimalarial treatment without a confirmation test (RDT or thick smear)			
188. Number of people who died of confirmed malaria			

	P	ear-Posit Pulmonar culosis (I	у	F	ear-nega Pulmonai rculosis (	ry	Extra-pulmonary Tuberculosis			
IV.1.2 TB CONTROL	0-4 years old	5-14 years old	years old and above	0-4 years old	5-14 years old	15 years old and above	0-4 years old	5-14 years old	15 years old and above	TOTAL
189. Number of suspected and referred cases										
190. Number of TB suspected cases referred to the laboratory for diagnosis										
191. Number of new cases										
192. Number of Relapses										
193. 114. Number of retreatment cases										
194. Number of treatment										
195. Number of Patients cured/Treatment completed										
196. Number of lost-to- follow-up Patients										
197. Number of referred Patients										
198. Number of TB patients who did the HIV test (with the result recorded in the register)										
199. Number of TB patients tested positive for HIV test										
200. Number of HIV positive TB patients on ARVs										
201. Number of TB patients on Cotrimoxazole										
202. Number of TB patients referred to the laboratory for follow-up										
203. Total number of drug- resistant TB patients										
204. Number of TB related deaths										
205. Number of health staff diagnosed TB+										

IV.2	NON CO	OMMUNIC	CA	BLE DISEASES CONTROL		
Diseases	New Cases	Death		Diseases	New Cases	Death
206. High blood pressure				207. Sickle-cell anaemia		
208. Diabetes				209. Gastric ulcer		
210. Stroke				211. Chronic visual disabilities		
212. Asthma				213. Chronic hearing disorders		
214. Epilepsy				215. Traumas		
216. Road traffic accidents				217. Mental illnesses		
218. Rheumatic diseases				219. Oral diseases		
220. Domestic violence				221. Rape		

IV.3 NEGLECTED TROPICAL DISEASES CONTROL												
Diseases	New Cases	New Cases	Death									
222. Onchocerciasis				223. Intestinal schistosomiasis								
224. Trachoma				225. Urinary schistosomiasis								
226. Leprosy				227. Guinea worm								
228. Buruli Ulcer				229. Yaws								
230. Human African Trypanosomiasis (HAT)				231. Leishmaniasis								
232. Helminthiasis												

IV.4 SURVEILLANCE OF VACCINE- PREVENTABLE DISEASES (VPDs)		233. Acute flaccid paralysis (AFP)	234. Neonatal tetanus (NNT)	235. Measles	236. Yellow fever
	Reported cases				
0-28 days	Investigated case				
	Death				
	Reported cases				
I-II months	Investigated case				
	Death				
12.50	Reported cases				
12-59 months	Investigated case				
	Death				
	Reported cases				
5-15 years old	Investigated case				
	Death				

IV.4 SURVEILLANCE OF VACCINE- PREVENTABLE DISEASES (VPDs)		233. Acute flaccid paralysis (AFP)	234. Neonatal tetanus (NNT)	235. Measles	236. Yellow fever
15 years	Reported cases				
old and	Investigated case				
more	Death				
	Vaccinated				
Immuniza tion status	Non-vaccinated				
	Unknown				

#### **IV.5** SURVEILLANCE OF EPIDEMIC-PRONE DISEASES AND OTHER PUBLIC HEALTH EVENTS New **Diseases New Cases Death Diseases Death Cases** 237. Meningitis 238. Varicella 239. Cholera 240. Genital ulcer (non vesicular) 241. Typhoid Fever 242. Plague 243. Bloody diarrhoea I 244. Rabies 245. Dracunculiasis 246. SARS (Atypical pneumopathy)

249. Viral Hepatitis B		250. Dengue	
251. Viral Hepatitis C		252. Smallpox	
253. Acute gastroenteritis		254. Urethral discharge	
255. Lymphatic filariasis		256. Dog bite	
257. Anthrax		258. Snake bite	
259. Chikungunya		260. Other envenomizations	

248. Flu syndrome

247. Viral haemorrhagic fevers2

<sup>&</sup>lt;sup>1</sup> Shigellosis; campylobacter; yersinia

<sup>&</sup>lt;sup>2</sup> Ebola, Marburg, Rift valley, Lassa, Congo crimea

## IV.6 INTEGRATED MANAGEMENT OF ACUTE MALNUTRITION (IMAM)

NOTE: Table to be completed only by HFs with the status of Ambulatory Nutritional Centre (ANC)

g in a	ning		Admission	S	Z -	ANSFER another	(0)	Transfer		Out	put		þ	Total at the end of the month
Age group	Total at the beginning of the month	C/G < -3 z- score or MUAC < 115 mm or MUAC < 180 mm	<b>СЕ</b> БЕМА	RELAPSE	RE-ADMISSION after Abandon (< 2 months)	-ADMISSI ter Aband < 2 month NAL TRA ITNC or a ANC)	Total of CNAS Admissions	INTERNAL TRANSFER (to ITNC or ANC)	HEALED	ABANDONED	DECEASED	NON RESPONDENT	Total Discharged	at the end month
6-59 months														
> 59 months														
TOTAL														
				-				%	%	%	%	%		

A = 0 = 110 110	Z	ew Admission	s
Age group	Girls	Boys	Total
6-59 months			
> 59 months			

Admission errors	
Average length of stay	

Intrants	In stock	Input	Output	Balanc e
RUTF (sachet)				
Amoxicillin				

NOTE: Table to be completed only by HFs with the status of Internal Therapeutic Nutritional Centre (ITNC)

		Nev	w Admission		RE-ADMISSION after Abandon (< 2 months) INTERNAL TRANSFER (from ITNC or another ITNC) Admissions			Output			P	f the		
Age group	Total at the beginning of the month	C/G < -3 z- score or MUAC < 115 mm or MUAC < 180 mm	<b>С</b> БЕМА	RELAPSE		Total of ITNC Admissions	Treated successfully	HEALED	ABANDONED	DECEASED	NON- RESPONDENT/ MEDICAL REFERENCES	Total Discharged	Total at the end of the month	
< 6 months														
6-59 months														
> 59 months														
TOTAL														
				_				%	%	%	%	%		

Age group	١	New Admissio	ns
	Girls	Boys	Total
< 6 months			
6-59 months			
> 59 months			

Admission errors	
Average length of stay	

Intrants	In stock	Input	Output	Balanc e
RUTF (sachet)				
Amoxicillin				
FI00 (sachet)				
ReSoMal (sachet)				

# **V. ACTIVITIES OF THE HEALTH FACILITY**

	1	lumber o	f cases pe	r age group	and per se	x
V.I Consultations/hospitalisations/Death	0 - 59 :	months	(exc	and above luding nt women)	Pregnant women	Total
	М	F	М	F		
261. Total number of consultations during the month						
262. Total number of beds available						
263. Total number of hospitalized patients during the month						
264. Total number of hospitalization days during the month						
265. Average length of stay in hospital						
266. Number of patients referred at an upper level during the month						
267. Total number of deaths recorded during the month						
268. Number of deaths declarations forwarded to the civil status centre during the month						

		Nun	nber per	age gro	up and բ	er sex	
V.2 10 Major reasons for consultation during the month	0 - 59	months	5-14 )	ears	15 years and above		% Total
	М	F	М	F	М	F	consultations
I-							
2-							
3-							
4-							
5-							
6-							
7-							
8-							
9-							
10-							

		Nu	mber per	age gro	up and	per sex	
V.3 10 Major causes of hospitalisation during the month	uring 0 - 59 months		5-14 y	5-14 years		ers and ove	% Total hospitalisations
	М	F	М	F	М	F	nospitansations
1-							
2-							
3-							
4-							
5-							
6-							
7-							
8-							

9-				
10-				

		Number	of deaths	per age	group	and per	sex
V.4 10 Major causes of death during the month	0 - 59	months	5-14 y	ears	15 years old and above		% Total
	М	F	М	F	М	F	deaths
1-							
2-							
3-							
4-							
5-							
6-							
7-							
8-							
9-							
10-							

V.I BLOOD TRANSFUSION	
269. Number of blood bags taken/collected	270. Number of blood bags transfused
271. Number of blood bags tested according to standards3	272. Number of blood bags served
273. Number of blood bags tested for HIV	274. Number of voluntary/unpaid donors
275. Number of HIV positive blood bags	276. Number of regular blood donors
277. Number of family blood donors	278. Number of blood bags destroyed
279. Number of blood donors tested for viral hepatitis B (HBV)	280. Number of blood donors tested positive for viral hepatitis B (HBV)
281. Number of blood donors tested for syphilis	282. Number of blood donors tested positive for syphilis
283. Number of blood donors tested for HIV	284. Number of blood donors tested positive for HIV
285. Number of co-infected HIV/HBV blood donors	286. Number of HIV positive blood donors referred to an MU
287. Number of mobile collections carried out during the month	288. Number of blood bags collected in fixed stations
289. Number of blood bags collected in mobile units	

<sup>&</sup>lt;sup>3</sup> HIV, Hepatitis, Syphilis

### VI. TRACER DRUGS

	Tracer drugs	Stock at the beginning of the month	Amount received during the month	Amount consumed	Temporary/occa sional help/ redeployment	Loss	Physical stock available during the month	Number of stock out days	Amount expiring <sup>4</sup>
I.	Nevirapine syrup	month					month		
2.	NVP 200 mg + 3TC 150 mg + AZT 300 mg orally								
3.	Efv 600 mg + 3tc 150 mg + tdf 300 mg orally								
4.	Artesunate injectable								
5.	Arthemeter injectable								
6.	Artesunate+amodiaquine 100mg/270mg tablet								
7.									
8.	Sulfadoxine pyrimethamine 500mg /25 mg orally								
9.	Arthemeter + lumefantrine 20/120 mg								
10.	Iron syrup								
11.	Folic acid + iron (25mg + 66 mg) tablet								
12.	Paracetamol 500 mg orally								
13.	Paracetamol 120 mg/5ml syrup bottle 100 mg								
14.	Paracetamol 100 mg orally								
15.	Tdr malaria								
16.	LLIN								
17.	Oral rehydration salt + Zinc Oxide								
18.	Doxycycline 100mg tablet								
19.	Ringer lactate solute 500 cc								
20.	Metronidazole 250 mg tablet								
21.	Metronidazole 125 mg/5ml syrup								
22.	Cotrimoxazole 480 mg tablet								
23.	Cotrimoxazole 240 mg/5 ml, oral solution								
24.	Amoxicillin 500 mg orally								

.

<sup>&</sup>lt;sup>4</sup> Expiry date less than 3 months.

25	A i -: II: 250 /5	1				
25.	Amoxicillin 250 mg/5ml syrup bottle 60 ml					
26	Ceftriaxone Ig, injection					
	ampoule					
27.	Glibenclamide 5mg orally					
28.	Mebendazole 100 mg/5 ml syrup					
29.	Aluminium hydroxide					
	500 mg					
30.	Omeprazole 20mg orally					
31.	lodised polyvidone 10%					
32.	Oxytocin 10 ui/ml, injectable					
33.	Dexamethasone 04 mg injectable					
34.	anti-tetanus serum					
35.	Antivenin serum					
36.	Diazepam					
37.	magnesium sulfate 1.5 g/10 ml injectable					
38.	Atropine 0.25 mg tablet					
39.	Fentanyl 100 mg, tablet					
	Furosemide 20 mg, injectable					
41.	lbuprofen 400 mg tablet					
42.	Rifampicine + INH+Pyrazinamide + Ethambutol					
43.	Mixtard human insulin,100 UI/10ml injectable					
44.	Progesterone-only pill					
45.	Oestrogen-Progesterone pill					
46.	Morning-after pill					
47.	Intramuscular Injections (Depo provera,)					
	Subcutaneous Injections (Sayana Press)					
49.	Implants					
50.	IUD					
51.	Male condoms					
52.	Female condoms					

VII. EPI INPUTS	Stock in the health facility (doses)	Stock lost (dose)	Stock used	Number of	l
-----------------	--------------------------------------	-------------------	------------	-----------	---

	Stock at the beginning of the month	Stock received during the month	Remaining stock at the end of the month	VVM changes colour	Frozen	expired/ Others	(dose of open bottle)	stock out days
B.C.G.								
OPV								
Нер В								
DTC-HepB +Hib (Penta)								
PNEUMO (PCV 13)								
Rota								
VPI								
RR								
VAA								
MenA								
TT								
Td								
HPV								
Vit_A 50 000 U.I.								
Vit_A 100 000 U.I.								
Vit_A 200 000 U.I.								
Syringe AB 0.05 ml BCG								
Syringe AB 0.5 ml								
Syringe Dil. 2 ml								
Syringe Dil. 5 ml								
Routine immunization card								
Safety box								

VIII. PHARMACOVIGILANCE	
290. Number of side effects reported during the month	
291. Number of serious side effects reported during the month	
292. Number of side effects reported and documented during the month	

# IX. COMMUNITY PARTICIPATION

293.Number of management committee meetings held during the month	
294.Number of Board of Directors meetings held during the month	

### **X. HOSPITAL FUNCTIONALITY**

	Number
295. Number of meetings of the hospital hygiene committee held during the month	
296. Number of days the incinerator was not operational	
297. Number of days the water treatment plant was not operational during the month	
298. Number of days the ambulance was not working during the month	
299. Number of days the electric generator had a break down during the month	
300. Number of days the mortuary was not working properly during the month	
301. Number of days the hospital was short of oxygen during the month	

### **XI. HUMAN RESOURCES**

Type of staff	Number of staff transferred to the HF	Workforce available	Retired workforce still in service
Health administrator			
Liaison officer			
Supervisor			
Cleaner			
Nursing Aid			
Social worker			
Health Technician			
Hearing Aid Practitioner			
Biologist			
Laundry worker-dressmaker			
Stretcher bearer			
Driver			
Surgeon			
Heart surgeon			
Maxillofacial surgeon			
Dental surgeon or Health Technician – dental hygiene			
Orthopaedic surgeon			
Thoracic surgeon			
Urologist surgeon			
Vascular surgeon			
Visceral surgeon			
Accountant/Superintendent/Cashier			
Cook			
Dermatologist			
Diabetologist endocrinologist			
Archivist			
Accommodation Laundry kitchen management HND			
Gynaecologist			
State Registered Nurse (generalist)			

State Registered Nurse (anaesthetist)		
Senior State Registered Nurse		
State Registered Nurse (childcare)		
State Registered Nurse (specialist)		
Senior Nurse		
Sanitary Engineer		
Gardener		
Legal officer		
General practitioner		
Pathologist		
Intensive care anaesthetist		
Restorative anaesthetist		
Medical biologist		
Nephrologist		
Neurologist		
Odontostomatologist		
Respirologist		
Psychiatrist		
Medical imaging radiologist		
Rhumathologist		
Medical specialist		
Urologist		
Speech therapist		
Paediatrician		
Support staff (seller, hostess, cashier)		
Ward staff		
Pharmacist		
Dental technician		
Administrative officer		
Administrative secretary		
Medical office secretary		
Midwife		
Statistician/computer engineer		
Cleaner		
Building technician		
Sanitary technician		
Hemodialysis Technician		
Biomedical maintenance technician		
Thanatopractor		
Health technician		
Laboratory technician		
Health technician Pharmaceutical sciences		
Health technician (imaging radiology)		
Senior nursing officer		
Other staff		

